BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1482 related articles for article (PubMed ID: 24857062)

  • 1. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Precision cancer medicine: the future is now, only better.
    Tsimberidou AM; Eggermont AM; Schilsky RL
    Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives on research activity in the USA on Cancer Precision Medicine.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2016 Feb; 46(2):106-10. PubMed ID: 26531706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.
    Govindan R; Mandrekar SJ; Gerber DE; Oxnard GR; Dahlberg SE; Chaft J; Malik S; Mooney M; Abrams JS; Jänne PA; Gandara DR; Ramalingam SS; Vokes EE
    Clin Cancer Res; 2015 Dec; 21(24):5439-44. PubMed ID: 26672084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 12. National Cancer Institute Basket/Umbrella Clinical Trials: MATCH, LungMAP, and Beyond.
    Chen AP; Eljanne M; Harris L; Malik S; Seibel NL
    Cancer J; 2019; 25(4):272-281. PubMed ID: 31335391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 15. Methodology of clinical trials in lung cancer.
    Menis J; Besse B; Lacombe D
    Chin Clin Oncol; 2015 Dec; 4(4):44. PubMed ID: 26730756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 18. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 20. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 75.